Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues

被引：11

作者：

Nagakawa, T

Kayahara, M

Ohta, T

Kitagawa, H

Mikami, K

Kurata, T

Otsuji, S

机构：

[1] Otsuka Pharmaceut Co Ltd, Dept Adv Pharmacol, Oncol & Immunol Res Inst, Tokushima 7710192, Japan

[2] Kanazawa Univ, Dept Hlth & Sci, Sch Med, Kanazawa, Ishikawa 920, Japan

[3] Kanazawa Univ, Sch Med, Dept Surg 2, Kanazawa, Ishikawa 920, Japan

[4] Otsuka Pharmaceut Co Ltd, Therapeut Applicat Dev Dept, Toyama Branch, Canc & Autoimmune Dis Div, Toyama, Japan

[5] Otsuka Pharmaceut Co Ltd, Therapeut Applicat Dev Dept, Sendai Branch, Canc & Autoimmune Dis Div, Sendai, Miyagi, Japan

来源：

CANCER INVESTIGATION | 2000年 / 18卷 / 06期

关键词：

D O I：

10.3109/07357900009012190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dihydropyrimidine dehydrogenase (DPD) activity was investigated using pancreatic tumors and normal pancreatic tissues surrounding the tumors obtained from 12 patients with pancreatic cancer. The mean DPD activity (+/- SD) was 2.69 +/- 1.88 nmol/mg protein/hr in normal pancreatic tissue and was 6.59 +/- 5.36 nmol/mg protein/hr in pancreatic tumor tissues. The DPD activity in tumor tissue was two- to threefold higher (p < 0.01) than that in normal tissue, but no marked difference was observed in DPD activity among cancer stages. The DPD activity of pancreatic tumors may be a useful clinical marker of the responsibility of fluorinated pyrimidine dosing in pancreatic cancer.

引用

页码：516 / 520

页数：5

共 15 条

[1] A ROLE FOR DIHYDROPYRIMIDINE DEHYDROGENASE AND THYMIDYLATE SYNTHASE IN TUMOR SENSITIVITY TO FLUOROURACIL [J].

BECK, A ;

ETIENNE, MC ;

CHERADAME, S ;

FISCHEL, JL ;

FORMENTO, P ;

RENEE, N ;

MILANO, G .

EUROPEAN JOURNAL OF CANCER, 1994, 30A (10) :1517-1522

[2]

DAH HL, 1986, ANTICANCER RES, V6, P781

[3] RESPONSE TO FLUOROURACIL THERAPY IN CANCER-PATIENTS - THE ROLE OF TUMORAL DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY [J].

ETIENNE, MC ;

CHERADAME, S ;

FISCHEL, JL ;

FORMENTO, P ;

DASSONVILLE, O ;

RENEE, N ;

SCHNEIDER, M ;

THYSS, A ;

DEMARD, F ;

MILANO, G .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1663-1670

[4]

FLEMING RA, 1992, CANCER RES, V52, P2899

[5] ANTITUMOR-ACTIVITY OF BOF-A2, A NEW 5-FLUOROURACIL DERIVATIVE [J].

FUJII, S ;

FUKUSHIMA, M ;

SHIMAMOTO, Y ;

OHSHIMO, H ;

IMAOKA, T ;

SHIRASAKA, T .

JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (02) :173-181

[6]

FUJII S, 1979, GANN, V70, P209

[7]

FUJITA F, 1993, JPN J CANC CHEMOTHER, V20, P223

[8]

MAEHARA Y, 1981, GANN, V72, P824

[9]

MATSUI Y, 1992, JPN SOC CANC THER, V27, P565

[10] EFFICACY OF A NEW 5-FLUOROURACIL DERIVATIVE, BOF-A2, IN ADVANCED NONSMALL CELL LUNG-CANCER - A MULTICENTER PHASE-II STUDY [J].

NAKAI, Y ;

FURUSE, K ;

OHTA, M ;

YAMAGUCHI, Y ;

FUJII, M ;

ASAKAWA, M ;

FUKUOKA, M ;

YOSHIDA, K ;

NIITANI, H .

ACTA ONCOLOGICA, 1994, 33 (05) :523-526

← 1 2 →